Novel analogues of arginine vasopressin containing α-2-indanylglycine enantiomers in position 2

Journal of Peptide Science

Volumn 16, Issue 1, 2010, Pages 15-20

  Kwiatkowska, Anna ^a   Śleszyńska, Małgorzta ^a   Derdowska, Izabela ^a   Prahl, Adam ^a   Sobolewski, Dariusz ^a   Borovičková, Lenka ^b   Slaninová, Jiřina ^b   Lammek, Bernard ^a  

^a UNIVERSITY OF GDA SK   (Poland)

^b INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY   (Czech Republic)

Author keywords

2 indanylglycine; Affinity to OT receptor; Antidiuretic hormone; Arginine vasopressin (AVP) analogues; Conformational restriction

Indexed keywords

2 AMINOINDANE 2 CARBOXYLIC ACID; ALPHA 2 INDANYLGLYCINE DERIVATIVE; ARGIPRESSIN; ARGIPRESSIN DERIVATIVE; CARBOXYLIC ACID DERIVATIVE; ESTROGEN; GLYCINE DERIVATIVE; INDAN DERIVATIVE; OXYTOCIN; OXYTOCIN RECEPTOR; PHENOXYBENZAMINE; TYROSINE; UNCLASSIFIED DRUG; UTEROTONIC AGENT; VASOPRESSIN; VASOPRESSIN V1A RECEPTOR; VASOPRESSIN V2 RECEPTOR;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIDIURESIS; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG DESIGN; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENANTIOMER; FEMALE; HUMAN; HUMAN CELL; MALE; NONHUMAN; PRESSOR RESPONSE; PRIORITY JOURNAL; RAT; STRUCTURE ACTIVITY RELATION; UTERUS CONTRACTION;

ANIMALS; ARGININE VASOPRESSIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, THIN LAYER; FEMALE; GLYCINE; INDANS; RATS; RATS, WISTAR; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; STEREOISOMERISM;

RATTUS;

EID: 74749088731     PISSN: 10752617     EISSN: 10991387     Source Type: Journal    
DOI: 10.1002/psc.1189     Document Type: Article

References (32)

1. Barberis C, Tribollet E. Vasopressin and oxytocin receptors in the central nervous system. Crit. Rev. Neurobiol. 1996; 10: 119-154.
2. Engelmann M, Wotjak CT, Neumann I, Ludwig M, Landgraf R. Behavioral consequences of intracerebral vasopressin and oxytocin: focus on learning and memory. Neurosci. Biobehav. Rev. 1996; 20: 341-358.
3. Ring RH. The central vasopressinergic system: examining the opportunities for psychiatric drug development. Curr. Pharm. Des. 2005; 11: 205-225.
4. JardS, BarberisC, AudigierS, TribolletE. Neurohypophyseal hormone receptor systems in brain and periphery. Prog. Brain Res. 1987; 72: 173-187.
5. Gimpl G, Fahrenholz F. The oxytocin receptor system: structure, function, and regulation. Physiol. Rev. 2001; 81: 629-683.
6. Barberis C, Morin D, Durroux T, Mouillac B, Guillon G, Seyer R, Hibert M, Tribollet E, Manning M. Molecular pharmacology of vasopressin and oxytocin receptors and therapeutic potential. Drug News Perspect. 1999; 12: 279-292.
7. Manning M, Sawyer WH. Discovery, development, and some uses of vasopressin and oxytocin antagonists. J. Lab. Clin. Med. 1989; 114: 617-632.
8. LeblM, Jošt K, Brtnik F. Tables of Analogs in Handbook of Neurohypophyseal Hormone Analogs, vol. 2, part 2, CRC Press: Boca Raton, FL, 1987; 127-267.
9. Manning M, Bankowski K, SawyerWH. Selective agonists and antagonists of vasopressin. In Vasopressin, Principles and Properties, Gash DM, Boer GJ (eds). Plenum Press: New York, 1987; 335-368.
10. Manning M, Grzonka Z, SawyerWH. Synthesis of posterior pituitary hormones and hormone analogues. In The Pituitary, BeardwellC, Robinson G (eds). Butterworth: Kent, 1981; 265-296.
11. Andersson KE, Arner B. Effects of DDAVP, a synthetic analogue of vasopressin, in patients with cranial diabetes insipidus. Acta Med. Scand. 1972; 192: 21-27.
12. Derdowska I, Prahl A, KowalczykW, Janecki M, MelhemS, Trzeciak HI, Lammek B. Influence of enantiomers of 1-naphthylalanine in position 2 of VAVP and DVAVP on their pharmacological properties. Eur. J.Med. Chem. 2005; 40: 63-68.
13. 2 agonists. Eur. J.Med. Chem. 2009; 44: 2862-2867.
14. KowalczykW, Sobolewski D, Prahl A, Derdowska I, Borovicková L, Slaninová J, Lammek B. The effects of N-terminal part modification of arginine vasopressin analogues with 2-aminoindane-2-carboxylic acid: a highly potent V2 agonist. J.Med. Chem. 2007; 50: 2926-2929.
15. Gera L, Stewart JM. A new class of bradykinin antagonists containing indanylglycine. Immunopharmacol 1996; 33: 174-177.
16. Stewart JM. Solid Phase Peptide Synthesis. Pierce Chemical Corporation: Rockford, 1984; 87.
17. Bodanszky M, Bodanszky A. The Practice of Peptide Synthesis. Springer-Verlag: Berlin, 1984; 83.
18. Kaiser E, Colescott RL, Bossinger CD, Cook PI. Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides. Anal. Biochem. 1970; 34: 595-598.
19. Christensen TC. A chloroanil color test for monitoring coupling completeness in solid-phase peptide synthesis. In Peptides - Structure and Biological Function, Gross E, Meienhofer J, (eds). Pierce Chemical Corporation: Rockford, 1979; 385.
20. Holton P. A modification of the method of Dale and Laidlaw for standardization of posterior pituitary extract. Br. J. Pharmacol. 1948; 3: 328-334.
21. Rudinger J, Krejci I. Dose-response relations for some synthetic analogues of oxytocin, and the mode of action of oxytocin on the isolated uterus. Experientia 1962; 18: 585-588.
22. Dekanski J. The quantitative assay of vasopressin. Br. J. Pharmacol. 1952; 7: 567-572.
23. Slaninová J. Fundamental Biological Evaluation. In Handbook of Neurohypophyseal Hormone analogs, Vol. 1, Part 2, Jošt K, Lebl M, Brtník F (eds). CRC Press: Boca Raton, 1987; 83-107.
24. Burn HJ, Finney DJ, Goodwin LG. Biological Standardization, 2nd edn, Oxford University Press: London, 1950; 187.
25. Vávra I, Machová A, Krejčí I. Antidiuretic action of 1-deamino-8-Darginine vasopressin in unanesthetized rats. J. Pharmacol. Exp. Ther. 1974; 188: 241-247.
26. Fahrenholz F, Boer R, Crause P, Fritzsch G, Grzonka Z. Interactions of vasopressin agonists and antagonists with membrane receptors. Eur. J. Pharmacol. 1984; 100: 47-58.
27. Gimpl G, Burger K, Fahrenholz F. Cholesterol as modulator of receptor function. Biochemistry 1997; 36: 10959-10974.
28. Soloff MS, Swartz TL. Characterization of a proposed oxytocin receptor in the uterus of the rat and sow. J. Biol. Chem. 1974; 249: 1376-1381.
29. Sobocińska M, Łempicka E, Konieczna E, Derdowska I, Lammek B, Melhem S, KozikW, Janecka J, Janecki M, Trzeciak HI. Analogues of arginine vasopressin modified in position 2 or 3 with naphthylalanine: selective antagonists of oxytocin in vitro. J. Pharm. Pharmacol. 2000; 52: 1105-1112.
30. Manning M, Miteva K, Pancheva S, Stoev S,Wo NC, Chan WY. Design and synthesis of highly selective in vitro and in vivo uterine receptor antagonists of oxytocin: comparisons with Atosiban. Int. J. Pep. Protein Res. 1995; 46: 244-252.
31. Flouret G, Chaloin O, Borovickova L, Slaninova J. Design of novel bicyclic analogues derived from a potent oxytocin antagonist. J. Peptide Sci. 2006; 12: 412-419.
32. Fragiadaki M, Magafa V, Borovickova L, Slaninova J, Cordopatis P. Synthesis and biological activity of oxytocin analogues containing conformationally-restricted residues in position 7. Eur. J.Med. Chem. 2007; 42: 799-806.